ChemicalBook > Product Catalog >API >Antineoplastic agents >Tinib Antineoplastic drugs >Sunitinib Malate

Sunitinib Malate

Sunitinib Malate Suppliers list
Company Name:Zhengzhou Topcare Pharmaceutical Co.,Ltd.  Gold
Company Name:Nanjing First Pharmaceutical Co., Ltd.  Gold
Tel:+86-25-83172655 /13776562784
Company Name:Jinan XuanHong Pharmaceutical Technology Co.,Ltd  Gold
Tel:86 0531-88801867 88801869 18678775975
Company Name:Target molecule Corp.  Gold
Company Name:Wuhan Biocar Bio-Pharm Co., Ltd.  Gold
Sunitinib Malate Basic information
Anticancer drug Uses
Product Name:Sunitinib Malate
Synonyms:SUNITINIB MALATE;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate;N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide(2S)-2-hydroxybutanedioatesalt;Sunitinib Malate(Sutent);Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide (1:1);N-(2-(DiethylaMino)ethyl)-5-((Z)-(5-fluoro-1,2-dih;Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide;(Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate
Product Categories:APIs;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;Tyrosine Kinase Inhibitors;SU-11248;Inhibitors;Oxetanes
Mol File:341031-54-7.mol
Sunitinib Malate Structure
Sunitinib Malate Chemical Properties
Melting point 189-191°C
storage temp. Store at +4°C
CAS DataBase Reference341031-54-7(CAS DataBase Reference)
Safety Information
Hazard Codes T
Risk Statements 61-2-48/25
Safety Statements 53-22-36/37
MSDS Information
Sunitinib Malate Usage And Synthesis
Anticancer drugSunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases.
Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy.
The indications of Sunitinib malate are as follows:
1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST).
2, inoperable advanced renal cell carcinoma (RCC).
3, advanced pancreatic endocrine tumors.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
UsesAnti-cancer drugs
Chemical PropertiesYellow Solid
UsageSunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
UsageSunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit
UsageA multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
Biological ActivityPotent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.
Sunitinib Malate Preparation Products And Raw materials
Tag:Sunitinib Malate(341031-54-7) Related Product Information
Sorafenib tosylate Sorafenib tosylate Dasatinib Erlotinib hydrochloride Ponatinib Ibrutinib Pyrrole (METHOXYMETHYL)DIPHENYLPHOSPHINE OXIDE Indole Sunitinib Malate Sunitinib SUNITINIB-D10